1. Sarıbulbul O. Acık Kalp Makinası, Ekstrakorporeal dolaşım. Ed: Duran E. Kalp ve Damar Cerrahisi (II. Cilt). 1. Baskı. Çapa Tıp Kitabevi, pp. 1047–1074. İstanbul, 2004.
2. Sahin I, Aydin S, Ozkan Y, Dagli AF, Akin KO, Guzel SP, Catak Z, Ozercan MR. Diet-induced obesity suppresses ghrelin in rat gastrointestinal tract and serum. Mol Cell Biochem. 2011. Article in Press.
3. Dag E, Aydin S, Ozkan Y, Erman F, Dagli AF, Gurger M. Alteration in chromogranin A, obestatin and total ghrelin levels of saliva and serum in epilepsy cases. Peptides. 2010;31(5):932-7.
4. Ellinor PT, Low AF, Macrae CA. Reduced apelin levels in lone atrial fibrillation. Eur Heart J. 2006;27(2):222-6.
5. Shichiri M, Ishimaru S, Ota T, Nishikawa T, Isogai T, Hirata Y. Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med. 2003;9(9):1166-1172.
6. Suzuki N, Shichiri M, Akashi T, Sato K, Sakurada M, Hirono Y, Yoshimoto T, Koyama T, Hirata Y. Systemic distribution of salusin expression in the rat. Hypertens Res. 2007;30(12):1255-1262.
7. Chong KS, Gardner RS, Ashley EA, Dargie HJ, McDonagh TA. Emerging role of the apelin system in cardiovascular homeostasis. Biomark Med. 2007;1(1):37–43. 8. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine.
Pharmacol Ther. 2005;107(2):198-211.
9. Mahar MA, Rainio A, Ilves M, Lindgren K, Kärjä-Koskenkari P, Taskinen P, Vuolteenaho O, Biancari F. Changes in natriuretic peptides, apelin and adrenomedullin after off-pump and on-pump coronary artery bypass surgery. J Cardiovasc Surg (Torino). 2008;49(6):783-91.
10. Norman AW, Litwack G. Hormones. Second Edition, Academic Press. pp. 418- 420, San Diego, California, USA, 1997.
11. Mesut R. Kardiyovasküler Anatomi. Ed: Duran E. Kalp ve Damar Cerrahisi (I. Cilt). 1. Baski, Capa Tıp Kitabevi, pp. 37-54, İstanbul, 2004.
12. Skwarek M, Grzybiak M, Kosiński A, Hreczecha J: Basic axes of human heart in correlation with heart mass and right ventricular wall thickness. Folia Morphol. 2006;65(4):385-389.
13. Sokołowska-Pituchowa J Anatomia człowieka. 6th ed. PZWL, Warszawa 2000. 14. Elghobary T, Légaré JF. What has happened to multiple arterial grafting in
coronary artery bypass grafting surgery? Expert Rev Cardiovasc Ther. 2010;8(8):1099-1105.
15. Atay Y, Yagdi T, Engin C, Ayik F, Oguz E, Alayunt A, Ozbaran M, Durmaz I. Effect of pleurotomy on blood loss during coronary artery bypass grafting. J Card Surg. 2009;24(2):122-126.
16. Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clin Chim Acta. 2010;14:411(23-24):1875-1882.
17. Miller YI, Choi SH, Fang L, Tsimikas S. Lipoprotein modification and macrophage uptake: role of pathologic cholesterol transport in atherogenesis. Subcell Biochem. 2010;51:229-251.
18. Alwaili K, Awan Z, Alshahrani A, Genest J. High-density lipoproteins and cardiovascular disease: 2010 update. Expert Rev Cardiovasc Ther. 2010;8(3):413- 423.
19. Gibbon J. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med. 1954;37:171–185.
20. Shellıto JG, Buck BH, Carreau EP, Robınson RH, Aytac A. The use of citrated blood in extracorporeal circulation. Am Surg. 1959;25:796–800.
21. Medimagazin (Klinikler), 2011, http://www.medimagazin.com.tr/clinics/tr-dicle- universitesi-tip-fakultesi-kalp-damar-cerrahisi-anabilim-dali-73-0-303.html
22. Davies LK. Hypotermia. Physiology and clinical use. In: Ed: Gravlee GP, Davis RF, Utley JR. Cardiopulmonary bypass. Baltimore: Wiliams & Wilins. 1993;140– 154.
23. Hessel EA II. Cardiopulmonary bypass circuitry and cannulation techniques. In: Ed: Gravlee GP, Davis RF, Utley JR. Cardiopulmonary Bypass. pp. 55, Baltimore: Williams & Wilkins, 1993.
25. Tagarakis GI, Tsilimingas NB. Heparin-coated extracorporeal circulation systems in heart surgery. Recent Pat Cardiovasc Drug Discov. 2009;4(3):177-179.
26. Creswell LL, Alexander JC, Ferguson TB, Lisbon A, Fleisher LA. Intraoperative interventions: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. American College of Chest Physicians Chest. 2005;128(Suppl 2):28-35.
27. Tennant M, McGeachie JK. Blood vessel structure and function: a brief update on recent advances.. Aust N Z J Surg. 1990;60(10):747-753.
28. Junqueria LC, Carneiro J, Kelley RO. Basic Histology, 9th ed. Appleton & Lange. 1998;202-217.
29. Gartner LP, Hiatt, JL. Color Texbook of Histology. pp. 213-229, W:B. Saunders of Company, 1997.
30. Lafleur MA, Madeleine M. Handsley and Dylan RE. Blood vessel structure. Cambridge University. Pres 2003;5.
31. Taggart D, D’Amico R, Altman D. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet. 2001;358:870-875.
32. Murray G. Blood vessel surgery. Can Med Assoc J. 1953;69(3):296-299.
33. Smıth S, Beasley M, Hodes R, Hall H, Biel E, Huth EW. Auxiliary myocardial vascularization by prosthetic graft implantation. Surg Gynecol Obstet. 1957;104(3):263-268.
34. Sabik JF, Stockins A, Nowicki ER, Blackstone EH, Houghtaling PL, Lytle BW, Loop FD. Does location of the second internal thoracic artery graft influence outcome of coronary artery bypass grafting? Circulation. 2008;30: 118(Suppl 14):210-215.
35. Fukui T, Tabata M, Manabe S, Shimokawa T, Takanashi S. Graft selection and one-year patency rates in patients undergoing coronary artery bypass grafting. Ann Thorac Surg. 2010;89(6):1901-1905.
36. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary artery bypass grafts. J Thorac Cardiovasc Surg. 1985;89:248- 258.
37. Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R, McCarthy PM, Cosgrove DM. Two internal thoracic arterygrafts are better than one. J Thorac Cardiovasc Surg. 1999;117:855-872.
38. Lytle BW, Blackstone EH, Sabik JF, Houghtaling P, Loop FD, CosgroveDM. The effect of bilateral internal thoracic artery grafting on survival during 20 postoperative years. Ann Thorac Surg. 2004;78:2005-2014.
39. Grover FL, Johnson RR, Marshall G, Hammermeister KE. Impact of mammary grafts on coronary bypass operative mortality and morbidity. Department of Veteran Affairs Cardiac Surgeons. Ann Thorac Surg. 1994;57:559-569.
40. Dabel RJ, Goss JR, Maynard C, Aldea GS. The effect of left internalmammary artery utilization on short-term outcomes after coronaryrevascularization. Ann Thorac Surg. 2003; 76: 464-470.
41. Crouch JD, O'Hair DP, Keuler JP, Barragry TP, Werner PH, Kleinman LH. Open versus endoscopic saphenous vein harvesting: wound complications and vein quality. Ann Thorac Surg. 1999;68(4):1513-1516.
42. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, Williams GW, Golding LA, Gill GC, Taylor PC, Sheldon WC, Proudfit WL. Influence of the internal-mammary artery graft on 10-year survival and other cardiac events. N Engl J Med. 1986;314: 1-6.
43. Cameron A, Davis KB, Green G, Schaff HV. Coronary bypass surgery with internal-thoracic-artery grafts-effects on survival over a 15-year period. N Engl J Med. 1996;334(4):216-220.
44. Fichelle JM , Cormier F, Franco G, Luizy F. What are the guidelines for using a venous segment for an arterial bypass? General review. J Mal Vasc. 2010;35(3):155-161
45. Kunlin J, Bitry-Boely C, Volnie B. Remarks on aortography. Rev Chir. 1950;69(9- 10):286-298.
46. Kocailik A, Basaran M, Ugurlucan M, Ozbek C, Kafali E, Yerebakan C, Selimoglu O, Banach M, Ucak A, Ogus TN, Us M. Papaverine solution improves preservation of saphenous vein grafts used during cardiac surgery. Acta Cardiol. 2008;63(4):445-449.
47. Alrawi SJ, Raju R, Alshkaki G, Acinapura AJ, Cunningham JN Jr. Saphenous vein endothelial cell viability: a comparative study of endoscopic and open saphenectomy for coronary artery bypass grafting. JSLS. 2001;5(1):37-45.
48. Kelsall CJ, Chester AH, Amrani M, Singer DR. C-type natriuretic peptide relaxes human coronary artery bypass grafts preconstricted by endothelin-1. Ann Thorac Surg. 2005;80(4):1347-1351.
49. Plass CA, Podesser BK, Prusa AM. Effect of blower-mister devices on vasoreactivity of coronary artery bypass grafts. J Thorac Cardiovasc Surg. 2010; 140 (4): 923-927.
50. Luu TN, Chester AH, O'Neil GS, Tadjkarimi S, Yacoub MH. Effects of vasoactive neuropeptides on human saphenous vein. Br Heart J. 1992;67(6):474-477.
51. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;20: 251(2):471-476.
52. Sato K, Koyama T, Tateno T, Hirata Y, Shichiri M. Presence of immunoreactive salusin-alpha in human serum and urine. Peptides. 2006;27(11):2561-2566.
53. Sato K, Sato T, Susumu T, Koyama T, Shichiri M. Presence of immunoreactive salusin-beta in human plasma and urine. Regul Pept. 2009;27:158(1-3):63-67. 54. Kimoto S, Sato K, Watanabe T, Suguro T, Koyama T, Shichiri M. Serum levels
and urinary excretion of salusin-alpha in renal insufficiency. Regul Pept. 2010;8:162(1-3):129-132.
55. Sato K, Fujimoto K, Koyama T, Shichiri M. Release of salusin-beta from human monocytes/macrophages. Regul Pept. 2010;8:162(1-3):68-72.
56. Nakayama C, Shichiri M, Sato K, Hirata Y. Expression of prosalusin in human neuroblastoma cells. Peptides. 2009;30(7):1362-1367.
57. Watanabe T, Suguro T, Sato K, Koyama T, Nagashima M, Kodate S, Hirano T, Adachi M, Shichiri M, Miyazaki A. Serum salusin-alpha levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients. Hypertens Res. 2008;31(3):463-468.
58. Watanabe T, Nishio K, Kanome T, Matsuyama TA, Koba S, Sakai T, Sato K, Hongo S, Nose K, Ota H, Kobayashi Y, Katagiri T, Shichiri M, Miyazaki A. Impact of salusin alpha and beta on human macrophage foam cell formation and coronary atherosclerosis. Circulation. 2008;5:117(5):638-648.
59. Wang Z, Takahashi T, Saito Y, Nagasaki H, Ly NK, Nothacker HP, Reinscheid RK, Yang J, Chang JK, Shichiri M, Civelli O. Salusin beta is a surrogate ligand of the mas-like G protein-coupled receptor MrgA1. Eur J Pharmacol. 2006;13:539(3):145-150.
60. Yu F, Zhao J, Yang J, Gen B, Wang S, Feng X, Tang C, Chang L. Salusins promote cardiomyocyte growth but does not affect cardiac function in rats. Regul Pept. 2004;15:122(3):191-197.
61. Izumiyama H, Tanaka H, Egi K, Sunamori M, Hirata Y, Shichiri M. Synthetic salusins as cardiac depressors in rat. Hypertension. 2005;45(3):419-425.
62. Charles CJ. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovasc Hematol Agents Med Chem. 2007;5(1):1-10. 63. Brailoiu GC, Dun SL, Yang J, Ohsawa M, Chang JK, Dun NJ. Apelin-
immunoreactivity in the rat hypothalamus and pituitary. Neurosci Lett. 2002;26:327(3):193-197.
64. Kalea AZ, Batlle D. Apelin and ACE2 in cardiovascular disease Curr Opin Investig Drugs. 2010;11(3):273-282.
65. Lee DK, George SR, O'Dowd BF. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci. 2006;27(4):190-194.
66. Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A, Bingol N, Kilic S, Bingol S, Erikci S. Plasma apelin is lower in patients with elevated LDL- cholesterol. Exp Clin Endocrinol Diabetes. 2007;115(7):428-432.
67. Hashimoto T, Kihara M, Imai N, Yoshida S, Shimoyamada H, Yasuzaki H, Ishida J, Toya Y, Kiuchi Y, Hirawa N, Tamura K, Yazawa T, Kitamura H, Fukamizu A, Umemura S. Requirement of apelin-apelin receptor system for oxidative stress- linked atherosclerosis. Am J Pathol. 2007;171(5):1705-1712.
68. Glassford AJ, Yue P, Sheikh AY, Chun HJ, Zarafshar S, Chan DA, Reaven GM, Quertermous T, Tsao PS. HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes. Am J Physiol Endocrinol Metab. 2007;293(6):1590-1596. 69. Cayabyab M, Hinuma S, Farzan M, Choe H, Fukusumi S, Kitada C, Nishizawa N,
Hosoya M, Nishimura O, Messele T, Pollakis G, Goudsmit J, Fujino M, Sodroski J. Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry. J Virol. 2000;74(24):11972- 11976.
70. Mitra A, Katovich MJ, Mecca A, Rowland NE. Effects of central and peripheral injections of apelin on fluid intake and cardiovascular parameters in rats. Physiol Behav. 2006;30:89(2):221-225.
71. De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C, Kordon C, Vaudry H, Moos F, Llorens-Cortes C. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin
neuron activity and vasopressin release. Proc Natl Acad Sci.
2004;13:101(28):10464-10469.
72. Schulz C, Paulus K, Lehnert H. Adipocyte-brain: crosstalk. Results Probl Cell Differ. 2010;52:189-201.
73. Lambrecht NW, Yakubov I, Zer C, Sachs G. Transcriptomes of purified gastric ECL and parietal cells: identification of a novel pathway regulating acid secretion. Physiol Genomics. 2006;13;25(1):153-165.
74. Kidoya H, Naito H, Takakura N. Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood. 2010;15:115(15):3166-3174. 75. Scott IC, Masri B, D'Amico LA, Jin SW, Jungblut B, Wehman AM, Baier H, Audigier Y, Stainier DY. The g protein-coupled receptor agtrl1b regulates early development of myocardial progenitors. Dev Cell. 2007;12(3):403-413.
76. Charles CJ, Rademaker MT, Richards AM. Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep. J Endocrinol. 2006;189(3):701-710.
77. Falcão-Pires I, Gonçalves N, Gavina C, Pinho S, Teixeira T, Moura C, Amorim MJ, Pinho P, Areias JC, Leite-Moreira A. Correlation between plasma levels of apelin and myocardial hypertrophy in rats and humans: possible target for treatment? Expert Opin Ther Targets. 2010;14(3):231-241.
78. Jia YX, Pan CS, Zhang J, Geng B, Zhao J, Gerns H, Yang J, Chang JK, Tang CS, Qi YF. Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept. 2006;15:133(1-3):147-154.
79. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;15:99(2-3):87-92.
80. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev. 2010;62(3):331-342.
81. Kojima Y, Kundu RK, Cox CM, Leeper NJ, Anderson JA, Chun HJ, Ali ZA, Ashley EA, Krieg PA, Quertermous T. Upregulation of the apelin-APJ pathway promotes neointima formation in the carotid ligation model in mouse. Cardiovasc Res. 2010;1:87(1):156-165.
82. Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, Dhillo W, Dakin C, Sajedi A, Ghatei M, Bloom S.The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun. 2002;15:291(5):1208-1212.
83. Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol. 2003;6:470(3):171-175.
84. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, Zheng L, Leeper NJ, Pearl NE, Patterson AJ, Anderson JP, Tsao PS, Lenardo MJ, Ashley EA, Quertermous T. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008;118(10):3343-3354.
85. Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol. 2006;28:553(1-3):222-228.
86. Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, Sharma S, Neilson I, Webb DJ, Megson IL, Flapan AD, Newby DE. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008;9:52(11):908-913.
87. Zhong JC, Huang DY, Liu GF, Jin HY, Yang YM, Li YF, Song XH, Du K. Efrtfects of all-trans retinoic acid on orphan receptor APJ signaling in spontaneously hypertensive rats. Cardiovasc Res. 2005;15:65(3):743-750.
88. Gurzu B, Petrescu BC, Costuleanu M, Petrescu G. Interactions between apelin and angiotensin II on rat portal vein. J Renin Angiotensin Aldosterone Syst. 2006;7(4):212-216.
89. Tiani C, Garcia-Pras E, Mejias M, de Gottardi A, Berzigotti A, Bosch J, Fernandez M. Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. J Hepatol. 2009;50(2):296-305.
90. Ringström C, Nitert MD, Bennet H, Fex M, Valet P, Rehfeld JF, Friis-Hansen L, Wierup N. Apelin is a novel islet peptide. Regul Pept. 2010;8:162(1-3):44-51. 91. Zhong JC, Huang Y, Yung LM, Lau CW, Leung FP, Wong WT, Lin SG, Yu XY.
The novel peptide apelin regulates intrarenal artery tone in diabetic mice. Regul Pept. 2007;4:144(1-3):109-114.
92. Mullens W, Bartunek J, Wilson Tang WH, Delrue L, Herbots L, Willems R, De Bruyne B, Goethals M, Verstreken S, Vanderheyden M. Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm. 2008;5(1):52- 59.
93. Ronkainen VP, Ronkainen JJ, Hänninen SL, Leskinen H, Ruas JL, Pereira T, Poellinger L, Vuolteenaho O, Tavi P. Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J. 2007;21(8):1821-1830.
94. Japp AG, Cruden NL, Barnes G, van Gemeren N, Mathews J, Adamson J, Johnston NR, Denvir MA, Megson IL, Flapan AD, Newby DE. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010;27:121(16):1818-1827.
95. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail. 2006;8(4):355-360.
96. Kojima Y, Quertermous T. Apelin-APJ signaling in retinal angiogenesis. Arterioscler Thromb Vasc Biol. 2008;28(10):1687-1688.
97. Kasai A, Shintani N, Kato H, Matsuda S, Gomi F, Haba R, Hashimoto H, Kakuda M, Tano Y, Baba A. Retardation of retinal vascular development in apelin-deficient mice. Arterioscler Thromb Vasc Biol. 2008;28(10):1717-1722.
98. Kasai A, Ishimaru Y, Kinjo T, Satooka T, Matsumoto N, Yoshioka Y, Yamamuro A, Gomi F, Shintani N, Baba A, Maeda S. Apelin is a crucial factor for hypoxia- induced retinal angiogenesis. Arterioscler Thromb Vasc Biol. 2010;30(11):2182- 2187.
99. Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, Yu F, Duan XH, Tang CS, Qi YF. Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides. 2007;28(10):2023-2029.
100.Chandrasekaran B, Kalra PR, Donovan J, Hooper J, Clague JR, McDonagh TA. Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction. J Card Fail. 2010;16(7):556-561.
101.Wang C, Du JF, Wu F, Wang HC. Apelin decreases the SR Ca2+ content but enhances the amplitude of [Ca2+] transient and contractions during twitches in isolated rat cardiac myocytes. Am J Physiol Heart Circ Physiol. 2008;294(6):2540- 2546.
102.Warner FJ, Smith AI, Hooper NM, Turner AJ. Angiotensin-converting enzyme-2: a molecular and cellular perspective. Cell Mol Life Sci. 2004;61(21):2704-2713. 103.Gao LR, Zhang NK, Bai J, Ding QA, Wang ZG, Zhu ZM, Fei YX, Yang Y, Xu
RY, Chen Y. The apelin-APJ pathway exists in cardiomyogenic cells derived from mesenchymal stem cells in vitro and in vivo. Cell Transplant. 2010;19(8):949-958 104.Kuklinska AM, Sobkowicz B, Sawicki R, Musial WJ, Waszkiewicz E, Bolinska S,
Małyszko J. Apelin: a novel marker for the patients with first ST-elevation myocardial infarction. Heart Vessels. 2010;25(5):363-7.
105.Hosoda H, Doi K, Nagaya N, Okumura H, Nakagawa E, Enomoto M, Ono F, Kangawa K. Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples. Clin Chem. 2004;50:1077-1080.
106.Stengel A, Keire D, Goebel M, Evilevitch L, Wiggins B, Taché Y, Reeve JR. The RAPID method for blood processing yields new insight in plasma concentrations and molecular forms of circulating gut peptides. Endocrinology. 2009;150(11):5113-5118.
107.Kojima M, Kangawa K. Ghrelin: structure and function. Physiol Rev. 2005;85:495- 522.
108.105-Crowther JR. Basic Principles of ELISA. Methods in Molecular Biology. 1995;42(1):35-61.
109.Hsu SM, Raine L, Fanger H. Use of avidin- biotin peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;9:577-580.
110.Raja SG, Amrani M. Reoperative off-pump coronary artery bypass grafting: current outcomes, concerns and controversies. Expert Rev Cardiovasc Ther. 2010;8(5):685-694.
111.Raja SG, Dreyfus GD. Current status of off-pump coronary artery bypass surgery. Asian Cardiovasc Thorac Ann. 2008;16(2):164-178.
112.Chassot PG, van der Linden P, Zaugg M, Mueller XM, Spahn DR. Off-pump coronary artery bypass surgery: physiology and anaesthetic management. Br J Anaesth. 2004;92(3):400-413.
113.Belloni AS, Guidolin D, Salmaso R, Bova S, Rossi GP, Nussdorfer GG. Adrenomedullin, ANP and BNP are colocalized in a subset of endocrine cells in the rat heart. Int J Mol Med. 2005;15(4):567-571.
114.Woodard GE, Rosado JA. Natriuretic peptides in vascular physiology and pathology. Int Rev Cell Mol Biol. 2008;268:59-93.
115.Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens. 2008; 21(7):733-741.
116.Moazami N, Oz MC. Natriuretic peptides in the perioperative management of cardiac surgery patients. Heart Surg Forum 2005;8(3):151-157.
117.Sato K, Koyama T, Shichiri M. Biosynthesis and secretion of salusin-alpha from human cells. Peptides. 2008;29(12):2203-2307.
118.Lewicki JA, Greenberg B, Yamanaka M, Vlasuk G, Brewer M, Gardner D, Baxter J, Johnson LK, Fiddes JC. Cloning, sequence analysis, and processing of the rat and human atrial natriuretic peptide precursors. Fed Proc. 1986;45(7):2086-2090. 119.Suzuki N, Shichiri M, Tateno T, Sato K, Hirata Y. Distinct systemic distribution of
salusin-α and salusin-β in the rat. Peptides. 2011;32(4):805-10.
120.Saito T, Dayanithi G, Saito J, Onaka T, Urabe T, Watanabe TX, Hashimoto H, Yokoyama T, Fujihara H, Yokota A, Nishizawa S, Hirata Y, Ueta Y. Chronic osmotic stimuli increase salusin-beta-like immunoreactivity in the rat hypothalamo- neurohypophyseal system: possible involvement of salusin-beta on [Ca2+]i increase and neurohypophyseal hormone release from the axon terminals. J Neuroendocrinol. 2008;20(2):207-219.
121.Nakhjavani M, Esteghamati A, Hamidi S, Esfahanian F, Nabavi H, Abbasi M, Mirkhani SH. Changes in growth hormone and insulin-like growth factor-I levels in the acute stage after open heart surgery and at the time of discharge. Exp Clin Endocrinol Diabetes. 2009;117(8):413-416.
122.Lazar HL, Bao Y, Siwik D, Frame J, Mateo CS, Colucci WS. Nesiritide enhances myocardial protection during the revascularization of acutely ischemic myocardium. J Card Surg. 2009;24(5):600-605.
123.Watanabe K, Ohta Y, Kouda T, Sekiguchi T, Sato S, Nakazawa M, Hasegawa G, Naito M, Fuse K, Ito M, Hirono S, Tanabe N, Hanawa H, Kato K, Kodama M, Aizawa Y. Acute effects of endothelin-1 and TAK-044 (ET(A) and ET(B) receptor antagonist) in rats with dilated cardiomyopathy. J Cardiovasc Pharmacol. 2000;36(Suppl 2):49-54.
124.Winterhalter M, Brandl K, Rahe-Meyer N, Osthaus A, Hecker H, Hagl C, Adams HA, Piepenbrock S. Endocrine stress response and inflammatory activation during CABG surgery. A randomized trial comparing remifentanil infusion to intermittent fentanyl. Eur J Anaesthesiol. 2008;25(4):326-335.
125.Lorenz RA, Lorenz RM, Codd JE. Perioperative blood glucose control during adult coronary artery bypass surgery. AORN J. 2005;81(1):126-144:147-150.
126.Liu Y, Sellke EW, Feng J, Clements RT, Sodha NR, Khabbaz KR, Senthilnathan V, Alper SL, Sellke FW. Calcium-activated potassium channels contribute to human skeletal muscle microvascular endothelial dysfunction related to cardiopulmonary bypass Surgery. 2008;144(2):239-244.